Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancreatin for diarrhea in Crohn's disease patients on total enteral nutrition
ChiCTR2200058343Phase 4Not yet recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Apr 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pancreatin in Crohn's disease, sponsored by Renmin Hospital of Wuhan University. Primary endpoint: Diarrhea remission rate. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
pancreatin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2200058343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058343.